On May 22nd, Tianjin Tianyao Pharmaceuticals Co.,Ltd., a subsidiary of the Group, announced that its subsidiary Tianjin Jin Yao Pharmaceutical Co., Ltd. had received the Drug Registration Certificate of terbutaline sulfate solution for atomizing inhalation approved and issued by National Medical Products Administration. It is learned that terbutaline sulfate aerosol inhalation solution is mainly used to relieve bronchospasm complicated by bronchial asthma, chronic bronchitis, emphysema and other lung diseases.

Terbutaline sulfate aerosol inhalation solution, as one of commonly used drugs for respiratory diseases, has a large market space. According to the hospital data of the national enlarged version of Menet, the domestic sales of terbutaline sulfate aerosol inhalation solution in 2021 and 2022 were 1.237 billion yuan and 1.25 billion yuan respectively. After the terbutaline sulfate aerosol inhalation solution of a subsidiary of Tianjin Tianyao Pharmaceuticals Co.,Ltd. obtains the Drug Registration Certificate this time, a positive impact will be brought on the company's expansion of the domestic preparation market and improvement of its future performance. 

In recent years, Tianjin Tianyao Pharmaceuticals Co.,Ltd. has actively implemented the whole industrial chain layout of "APIs plus preparations" around the core of steroid hormones and amino acids. Among them, the annual sales revenue of several key varieties in the pharmaceutical preparations business of Tianjin Tianyao Pharmaceuticals Co.,Ltd. has exceeded 100 million yuan, including famotidine injection, hydrocortisone butyrate cream, methylprednisolone sodium succinate for injection, norepinephrine bitartrate injection, methylprednisolone tablets, and compound amino acid injection for children. With the continuous improvement of the preparation product cluster, there are still many potential varieties to be broken in the sales market of Tianjin Tianyao Pharmaceuticals Co.,Ltd., which is expected to bring new profit growth points to the company in the future.